Theratechnologies Inc T.TH

Nash tag conference

[Bucknelly21]

How can a phase 3 Nash company like Thtx get lost in the mix of 2-3 others?!? They apparently are going to a Nash tag conference in Utah and aren't even presenting? They have a booth lol so embarrassing how much they botched the Nash opportunity

[stephanedodier]

Here is the link https://www.nash-tag.org/sponsors Madrigal is the main sponsor     https://9a944010-6d83-49a8-8995-84b445e0243f.filesusr.com/ugd/dcb143_612efdbc17a045ccbabcd86c3a0628c7.pdf  

[Wino115]

Hopefully they hand out samples  /s

[qwerty22]

I'm just glad they are there. They haven't dosed any patients, there's no data to present. 

[SPCEO1]

Well, for starters, it is more accurately described as phase III ready than just phase III. Then you have the history of the program, which is unconventional to say the least and needed several miracles to occur to get to the point of being phase III ready. But while we celebrate the incredible job the company did toy get to this point, most observers look at their phase III NASH asset and don'

[SABBOBCAT]

You could look at this in a few ways, 1) they couldnt get a presentation slot because no-one likes them or the unconventional path, 2) MDGL is the lead sponsor and doesnt want to highlight the competition, 3) They are far enough down a partnership path that they dont want need to pay up to market and/or don't want to piss off the new partner by shopping it around further.  I'd like

[palinc2000]

I think option 4 is the correct answer Option 4 .....All of the above!!!

[qwerty22]

Harrison is organizing NASH-TAG. There's a podcast here where he previews the meeting. https://surfingnash.com/s2-e60-explore-major-events-and-issues-for-nafld-and-nash-at-our-nash-tag-2022-preview/ He does mention that not all the oral presentations have been decided upon or announced yet. Also I was on the Nash-tag website a week or two ago and specifically checked for Thera on the

[qwerty22]

I should have said the discussion of session 9 around trial endpoints and regulatory issues looks the most promising.